[Cellular protection in acute myocardial infarction with ST-segment elevation]

Area of Science:

• Cardiology
• Pharmacology
• Biomedical Engineering

Context:

• Acute myocardial infarction (AMI) affects millions globally, with microcirculatory dysfunction persisting post-recanalization in approximately 50% of patients.
• Impaired microcirculatory blood flow is linked to adverse cardiac events and poorer prognosis despite successful epicardial artery revascularization.
• Current therapeutic strategies focus on reperfusion, but protecting the myocardial microcirculation remains a significant clinical challenge.

Purpose:

• To review and analyze existing and emerging pharmacological interventions aimed at improving myocardial microcirculatory blood flow after AMI.
• To evaluate the efficacy of medications targeting inflammatory responses and metabolic pathways in the context of ischemia-reperfusion injury.
• To highlight the need for novel therapeutic approaches and further clinical investigation due to inconclusive results from current treatments.

Summary:

• Successful fibrinolysis or primary percutaneous coronary artery rechanneling for AMI does not guarantee normal microcirculatory blood flow in about half of patients.
• Investigated coadjuvant medications include anti-inflammatory agents (anti-CD11/CD18 antibodies, anti-complement) and metabolic enhancers (glucose-insulin-potassium, Na+/H+ ion exchange inhibitors).
• Despite therapeutic efforts, outcomes have been inconclusive, underscoring the necessity for new studies to address this critical aspect of cardiac recovery.

Impact:

• Identifies key therapeutic targets for improving microcirculatory function in AMI patients.
• Provides a foundation for designing future clinical trials focused on myocardial protection strategies.
• Aims to reduce infarct size, preserve cardiac function, and improve long-term outcomes for patients surviving acute myocardial infarction.